



LIFE SCIENCES RESEARCH FOUNDATION

**FINANCIAL STATEMENTS
AND SUPPLEMENTARY INFORMATION**

MAY 31, 2013 AND 2012

TABLE OF CONTENTS

	<u>Page Numbers</u>
Independent Accountant's Review Report.....	1
Statements of Assets, Liabilities and Net Assets - Modified Cash Basis	2
Statements of Support and Revenue, Expenses and Changes in Net Assets - Modified Cash Basis.....	3-4
Statements of Cash Flows - Modified Cash Basis	5
Notes to Financial Statements	6-12
Supplementary Information:	
Schedules of Research Grants Paid.....	13-14
Schedules of Administrative Expenses	15

To the Board of Trustees
Life Sciences Research Foundation

Independent Accountant's Review Report

We have reviewed the accompanying statements of assets, liabilities, and net assets - modified cash basis of Life Sciences Research Foundation as of May 31, 2013 and 2012, and the related statements of support and revenue, expenses, and changes in net assets - modified cash basis and cash flows - modified cash basis for the years then ended. A review includes primarily applying analytical procedures to management's financial data and making inquiries of Life Sciences Research Foundation's management. A review is substantially less in scope than an audit, the objective of which is the expression of an opinion regarding the financial statements as a whole. Accordingly, we do not express such an opinion.

Management is responsible for the preparation and fair presentation of the financial statements in accordance with the modified cash basis of accounting and for designing, implementing, and maintaining internal control relevant to the preparation and fair presentation of the financial statements.

Our responsibility is to conduct the review in accordance with Statements on Standards for Accounting and Review Services issued by the American Institute of Certified Public Accountants. Those standards require us to perform procedures to obtain limited assurance that there are no material modifications that should be made to the financial statements. We believe that the results of our procedures provide a reasonable basis for our report.

Based on our review, we are not aware of any material modifications that should be made to the accompanying financial statements in order for them to be in conformity with the modified cash basis of accounting described in Note 1.

Our review was made for the purpose of expressing a conclusion that there are no material modifications that should be made to the financial statements in order for them to be in conformity with the modified cash basis of accounting. The accompanying supplementary information is presented only for purposes of additional analysis and is not a required part of the basic financial statements. Such information been subjected to the inquiry and analytical procedures applied in the review of the basic financial statements, and we are not aware of any material modifications that should be made to such information.

Gross, Mendelsohn & Associates, P.A.

Baltimore, Maryland
August 16, 2013

LIFE SCIENCES RESEARCH FOUNDATION
Statements Of Assets, Liabilities And Net Assets - Modified Cash Basis
May 31, 2013 and 2012

(See Independent Accountant's Review Report)

	<u>2013</u>	<u>2012</u>
Assets		
Cash and cash equivalents	\$ 1,302,990	\$ 1,338,069
Certificates of deposits	880,000	875,000
Investments	64,528	-0-
Deposits	25,000	-0-
Total Assets	<u>\$ 2,272,518</u>	<u>\$ 2,213,069</u>
Liabilities And Net Assets		
Liabilities		
Restricted grant advances	\$ 1,367,137	\$ 1,310,854
Escrow payable	84,365	84,185
Total Liabilities	<u>1,451,502</u>	<u>1,395,039</u>
Commitments (Note 3)		
Net Assets		
Unrestricted	735,106	748,035
Temporarily restricted	85,910	69,995
Total Net Assets	<u>821,016</u>	<u>818,030</u>
Total Liabilities and Net Assets	<u>\$ 2,272,518</u>	<u>\$ 2,213,069</u>

The accompanying notes are an integral part of these financial statements.

LIFE SCIENCES RESEARCH FOUNDATION
Statements Of Support And Revenue, Expenses
And Changes In Net Assets - Modified Cash Basis
Years Ended May 31, 2013 and 2012

(See Independent Accountant's Review Report)

	2013		
	Unrestricted	Temporarily Restricted	Total
Support and Revenue			
Restricted grants	\$ 3,119,288	\$ -0-	\$ 3,119,288
Unrestricted grants	61,360	-0-	61,360
Restricted contributions	-0-	45,915	45,915
Unrestricted contributions	1,375	-0-	1,375
Investment income	17,559	-0-	17,559
Grant forfeitures	79,333	-0-	79,333
Escrow forfeitures	11,026	-0-	11,026
Net assets released from restrictions:			
Satisfaction of program restrictions	30,000	(30,000)	-0-
Total Support and Revenue	<u>3,319,941</u>	<u>15,915</u>	<u>3,335,856</u>
Expenses:			
Program services			
Research grants paid	3,204,419	-0-	3,204,419
Supporting services			
Administrative expenses	128,114	-0-	128,114
Fund-raising expenses	337	-0-	337
Total supporting services	<u>128,451</u>	<u>-0-</u>	<u>128,451</u>
Total Expenses	<u>3,332,870</u>	<u>-0-</u>	<u>3,332,870</u>
Change in Net Assets	(12,929)	15,915	2,986
Net Assets, Beginning of Year	<u>748,035</u>	<u>69,995</u>	<u>818,030</u>
Net Assets, End of Year	<u>\$ 735,106</u>	<u>\$ 85,910</u>	<u>\$ 821,016</u>

The accompanying notes are an integral part of these financial statements.

2012

Unrestricted	Temporarily Restricted	Total
\$ 2,606,110	\$ -0-	\$ 2,606,110
61,120	-0-	61,120
-0-	69,995	69,995
250	-0-	250
18,835	-0-	18,835
28,000	-0-	28,000
-0-	-0-	-0-
-0-	-0-	-0-
<u>2,714,315</u>	<u>69,995</u>	<u>2,784,310</u>
<u>2,601,556</u>	-0-	<u>2,601,556</u>
83,084	-0-	83,084
640	-0-	640
<u>83,724</u>	-0-	<u>83,724</u>
<u>2,685,280</u>	-0-	<u>2,685,280</u>
29,035	69,995	99,030
<u>719,000</u>	-0-	<u>719,000</u>
<u>\$ 748,035</u>	<u>\$ 69,995</u>	<u>\$ 818,030</u>

The accompanying notes are an integral part of these financial statements.

LIFE SCIENCES RESEARCH FOUNDATION
Statements Of Cash Flows - Modified Cash Basis
Years Ended May 31, 2013 and 2012

(See Independent Accountant's Review Report)

	<u>2013</u>	<u>2012</u>
Cash Flows From Operating Activities		
Change in net assets	\$ 2,986	\$ 99,030
Adjustments to reconcile change in net assets to net cash provided by operating activities:		
Loss on investments	167	-0-
Changes in operating assets and liabilities:		
Restricted grant advances	56,283	556,188
Escrow payable	180	27,981
Net Cash Provided by Operating Activities	<u>59,616</u>	<u>683,199</u>
Cash Flows From Investing Activities		
Purchase of investments	(64,695)	-0-
Decrease (Increase) in certificates of deposit	(5,000)	340,000
Deposits	(25,000)	-0-
Net Cash Provided by (Used in) Financing Activities	<u>(94,695)</u>	<u>340,000</u>
Net Increase (Decrease) in Cash and Cash Equivalents	(35,079)	1,023,199
Cash and Cash Equivalents at Beginning of Year	<u>1,338,069</u>	314,870
Cash and Cash Equivalents at End of Year	<u>\$ 1,302,990</u>	<u>\$ 1,338,069</u>

The accompanying notes are an integral part of these financial statements.

LIFE SCIENCES RESEARCH FOUNDATION
Notes To Financial Statements
May 31, 2013 and 2012

(See Independent Accountant's Review Report)

Note 1: Summary of Significant Accounting Policies

Life Sciences Research Foundation (the Foundation) has been recognized by the Internal Revenue Service as a tax-exempt organization as defined by §501(c)(3) of the Internal Revenue Code (IRC). The Foundation was incorporated in the District of Columbia on June 25, 1981, for the purpose of funding basic research in the biological sciences at various institutions. Postdoctoral fellowships are awarded to qualifying scientists selected by the Foundation's peer review committee. Funds to support the fellowships come from corporate sponsors and other foundations.

In a prior year, the Foundation elected to be treated as a qualified fund under IRC §41(e)(6)(D). This election allowed the Foundation to be treated as a pass-through qualifying organization, thereby enabling corporate contributions to be eligible for the credit for increased research activities. As a qualifying fund, the Foundation was subject to the rules governing private foundations. Effective June 1, 2010, the Foundation elected to terminate its private foundation status in order to be treated as a publicly-supported organization.

The accounting and reporting policies of the Foundation conform to the modified cash basis of accounting, which is a comprehensive basis of accounting other than accounting principles generally accepted in the United States of America. Following is a description of the most significant of those policies:

Method of Accounting: The financial statements have been prepared on the modified cash basis of accounting, with investments stated at fair value and with the deferral of restricted grant revenue, which is recognized as revenue in proportion to the research grants paid. This basis differs from accounting principles generally accepted in the United States of America primarily because the Foundation has not recognized receivables, prepayments, and payables.

Financial Statement Presentation: The Foundation is required to report information according to three classes of net assets: unrestricted net assets, temporarily restricted net assets, and permanently restricted net assets. The Foundation only had unrestricted and temporarily restricted net assets as of May 31, 2013 and 2012.

Cash and Cash Equivalents: The Foundation classifies all investments which are readily convertible to cash and which have a maturity of three months or less when purchased as cash equivalents.

The Foundation maintains its cash balances at one financial institution. Periodically during the year, the Foundation's cash balances have exceeded federally insured limits. The Foundation has not experienced any losses in such accounts and believes it is not exposed to significant risk on cash balances.

Investments: Investments with readily determinable fair market values are reported at fair value in the statements of assets, liabilities and net assets - modified cash basis. Investments whose fair market values are not readily determinable are recorded at cost. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Realized and unrealized gains and losses on investments for the year are reported in the statements of support and revenue, expenses and changes in net assets - modified cash basis.

LIFE SCIENCES RESEARCH FOUNDATION
Notes To Financial Statements
May 31, 2013 and 2012

(See Independent Accountant's Review Report)

Note 1: Summary of Significant Accounting Policies (Continued)

The Foundation invests in a professionally managed portfolio that contains mutual funds and exchange-traded and closed-end funds. Such investments are exposed to various risks such as interest rate, market and credit. Due to the level of risk associated with such investments and the level of uncertainty related to changes in the value of such investments, it is at least reasonably possible that changes in risks in the near term would materially affect investment balances and the amounts reported in the financial statements.

Contributions and Grants: Contributions received and grants paid by the Foundation are presented at their market value on the date of such contribution or grant. For tax purposes, the Foundation records all contributions received at the donor's basis.

Revenue Recognition and Restricted Grant Advances: Substantially all of the Foundation's revenue is derived from restricted grants, which are recognized as revenue in proportion to the research grants paid. Unexpended research grants received are recorded as restricted grant advances in the statements of assets, liabilities, and net assets - modified cash basis. All other sources of revenue, such as unrestricted and temporarily restricted contributions and investment income, are recognized when received.

Contributions: Contributions received are recorded as unrestricted, temporarily restricted, or permanently restricted support depending on the existence and/or nature of any donor restrictions.

Recognition of Donor Restrictions: Donor-restricted support is reported as an increase in temporarily or permanently restricted net assets, depending on the nature of the restriction. Upon the expiration of a restriction, temporarily restricted net assets are reclassified to unrestricted net assets in the statements of support and revenue, expenses, and changes in net assets - modified cash basis.

Federal income tax: The Foundation is exempt from federal and state income taxes under §501(c)(3) of the IRC. Income that is not related to exempt purposes, less applicable deductions, is subject to federal and state income taxes. The Foundation had no unrelated business income for the years ended May 31, 2013 and 2012. Accordingly, no provision for income taxes is reflected in these financial statements. The Foundation's federal exempt organization tax returns are subject to examination by the IRS, generally for a period of three years after the returns are filed.

Subsequent Events: In preparing these financial statements, the Foundation has evaluated events and transactions for potential recognition or disclosure through August 16, 2013, the date the financial statements were available to be issued. During the period from June 1, 2013 through August 16, 2013, the Foundation did not have any material recognizable subsequent events.

LIFE SCIENCES RESEARCH FOUNDATION
Notes To Financial Statements
May 31, 2013 and 2012

(See Independent Accountant's Review Report)

Note 2: Investments and Fair Value Measurement (Continued)

The Foundation's investments, at fair value, as of May 31, 2013 and 2012 consisted of the following:

	<u>2013</u>	<u>2012</u>
Exchange-Traded & Closed-End Funds	<u>\$ 64,528</u>	<u>\$ -0-</u>

Investment income for the years ended May 31, 2013 and 2012 consisted of the following:

	<u>2013</u>	<u>2012</u>
Interest Income	\$ 17,726	\$ 18,835
Loss on investments	(167)	\$ -0-
Total Investment income	<u>\$ 17,559</u>	<u>\$ 18,835</u>

The FASB's fair value measurement standard establishes a framework for measuring fair value. The framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements).

The three levels of the fair value hierarchy are as follows:

Level 1: Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Foundation has the ability to access.

Level 2: Inputs to the valuation methodology include:

- Quoted prices for similar assets or liabilities in active markets;
- Quoted prices for identical or similar assets or liabilities in inactive markets;
- Inputs other than quoted prices that are observable for the asset or liability;
- Inputs that are derived principally from or corroborated by observable market data by correlation or other means

If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term of the asset or liability.

Level 3: Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

LIFE SCIENCES RESEARCH FOUNDATION
Notes To Financial Statements
May 31, 2013 and 2012

(See Independent Accountant's Review Report)

Note 2: Investments and Fair Value Measurement (Continued)

The asset's or liability's fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs. The valuation techniques used by the Foundation include the following:

Mutual Funds, Exchange-Traded & Closed-End Funds: Valued at the last sales price reported in the active market in which the individual fund is traded.

In determining the appropriate levels, the Foundation performs a detailed analysis of the assets and liabilities that are subject to fair value measurements.

The table below presents the balances of assets as of May 31, 2013 measured at fair value on a recurring basis by level within the hierarchy.

	Total	Level 1	Level 2	Level 3
Exchange-Traded & Closed-End Funds	\$ 64,528	\$ 64,528	\$ -0-	\$ -0-

The unrealized loss of \$167 is included with investment income on the statements of support and revenue, expenses and changes in net assets - modified cash basis.

Note 3: Commitments and Restricted Grant Advances

The Foundation's grant commitments resulted from the fellowship awards made by the Foundation's peer review committee. Most fellowships pay an established amount annually for a three-year period. For fellowships awarded on or before May 31, 2012, the annual amount is \$56,000 and commencing June 1, 2012, the annual amount is \$60,000. All committed amounts have been pledged by the sponsoring donors. As of May 31, 2013 and 2012, the Foundation had received \$1,367,137 and \$1,310,854, respectively, of the pledged amount from the sponsors. This amount is reflected on the statements of assets, liabilities, and net assets - modified cash basis as restricted grant advances.

LIFE SCIENCES RESEARCH FOUNDATION

Notes To Financial Statements

May 31, 2013 and 2012

(See Independent Accountant's Review Report)

Note 2: Commitments and Restricted Grant Advances (Continued)

As of May 31, 2013, the Foundation was committed to make the following grants:

Recipient	Sponsor	Commitment From Program Years				Total
		2013	2012	2011	2010	
Christopher Baker, Ph.D	The Gordon and Betty Moore Foundation	\$ 180,000				\$ 180,000
Kirk Burkhardt, Ph.D	Sanofi	180,000				180,000
David Burns, Ph.D	Howard Hughes Medical Institute	180,000				180,000
Ashesh Dhawale, Ph.D	The Ellison Medical Foundation/AFAR	180,000				180,000
Brian Duistermars, Ph.D	The Ellison Medical Foundation/AFAR	180,000				180,000
Sara Di Rienzi, Ph.D	Eli and Edythe Broad	180,000				180,000
Mohammad Fallahi-Sichani	Merck Research Laboratories	180,000				180,000
Elsa Bou Ghanem, Ph.D	Howard Hughes Medical Institute	180,000				180,000
Federico Gherardini, Ph.D	Howard Hughes Medical Institute	180,000				180,000
Nora Grahl, Ph.D	Howard Hughes Medical Institute	180,000				180,000
Leon Grayfer, Ph.D	Howard Hughes Medical Institute	180,000				180,000
Robin Harris, Ph.D	The Ellison Medical Foundation/AFAR	180,000				180,000
Nicholas Heaton, Ph.D	Merck Research Laboratories	180,000				180,000
William Housley, Ph.D	Pfizer	180,000				180,000
Chi-Kuo Hu, Ph.D	The Ellison Medical Foundation/AFAR	180,000				180,000
Philip Kranzusch, Ph.D	Howard Hughes Medical Institute	180,000				180,000
Keren Lasker, Ph.D	The Gordon and Betty Moore Foundation	180,000				180,000
Efrem Lim, Ph.D	Eli and Edythe Broad	180,000				180,000
Wei-Ting Liu, Ph.D	Simons Foundation	180,000				180,000
David Loehlin, Ph.D	Howard Hughes Medical Institute	180,000				180,000
Arundhati Maheshwari, Ph.D	The Gordon and Betty Moore Foundation	180,000				180,000
James Marshel, Ph.D	Simons Foundation	180,000				180,000
Rahul Palchaudhuri, Ph.D	The Jake Wetchler Foundation	180,000				180,000
Jun-Wei Pek, Ph.D	Howard Hughes Medical Institute	180,000				180,000
Priya Rajasethupathy, Ph.D	The Ellison Medical Foundation/AFAR	180,000				180,000
Constance Richter, Ph.D	Simons Foundation	180,000				180,000
Bryan Schmidt, Ph.D	Life Science Research Foundation	180,000				180,000
Alecia Septer, Ph.D	The Gordon and Betty Moore Foundation	180,000				180,000
Joshua Weinstein, Ph.D	Simons Foundation	180,000				180,000
Rayka Yokoo, Ph.D	Simons Foundation	180,000				180,000
Naupaka Zimmerman, Ph.D	The Gordon and Betty Moore Foundation	180,000				180,000
Anand Balasubramani, Ph.D	Howard Hughes Medical Institute		\$ 112,000			112,000
Harvey Chin, Ph.D	Merck Research Laboratories		112,715			112,715
Seemay Chou, Ph.D	Howard Hughes Medical Institute		112,000			112,000
David Dodd, Ph.D	ISIS Pharmaceuticals		112,000			112,000
Jamie Fitzgerald, Ph.D	The Ellison Medical Foundation/AFAR		112,000			112,000
Gregory Hamilton, Ph.D	Genetech Foundation		112,000			112,000
Euseok Kim, Ph.D	Biogen IDEC		112,000			112,000
Tung Le, Ph.D	The Gordon and Betty Moore Foundation		112,000			112,000
Amy Ma, Ph.D	Howard Hughes Medical Institute		112,000			112,000
Daniel Mandell, Ph.D	Howard Hughes Medical Institute		112,000			112,000
Mathieu Mateo, Ph.D	Merck Research Laboratories		112,000			112,000
Alison Narayan, Ph.D	Life Science Research Foundation		112,000			112,000
Ting Pang, Ph.D	Howard Hughes Medical Institute		112,000			112,000
Alexandre Persat, Ph.D	The Gordon and Betty Moore Foundation		112,000			112,000
Monica Rodrigo - Brenni, Ph.	The Ellison Medical Foundation/AFAR		112,000			112,000
Hannah Seidel, Ph.D	The Ellison Medical Foundation/AFAR		112,000			112,000
Mark Sheffield, Ph.D	The Ellison Medical Foundation/AFAR		112,000			112,000
Anthony Studer, Ph.D	Department of Energy		112,000			112,000
Elizabeth Thatcher, Ph.D	Howard Hughes Medical Institute		112,000			112,000
Yusuf Tufail, Ph.D	Howard Hughes Medical Institute		112,000			112,000
Rachel Vannette, Ph.D	The Gordon and Betty Moore Foundation		112,000			112,000
Michael White, Ph.D	Howard Hughes Medical Institute		112,000			112,000
Joshua Widhalm, Ph.D	The Gordon and Betty Moore Foundation		112,000			112,000
Li Yang, Ph.D	The Gordon and Betty Moore Foundation		112,000			112,000
Justin Ashworth, Ph.D	The Gordon and Betty Moore Foundation			\$ 56,000		56,000
Hoo Sun Chung, Ph.D	The Gordon and Betty Moore Foundation			56,000		56,000
Julio Cordero, Ph.D	Lilly Research Laboratories			56,000		56,000
Magdia De Jesus, Ph.D	Howard Hughes Medical Institute			56,000		56,000
Ylli Doksani, Ph.D	The Ellison Medical Foundation/AFAR			42,000		42,000
Cara Haney, Ph.D	The Gordon and Betty Moore Foundation			56,000		56,000
Karen Litwa, Ph.D	Howard Hughes Medical Institute			56,000		56,000
Cora MacAlister, Ph.D	The Gordon and Betty Moore Foundation			56,000		56,000
Babak Momeni, Ph.D	The Gordon and Betty Moore Foundation			56,000		56,000
Gautham Nair, Ph.D	Howard Hughes Medical Institute			56,000		56,000
Jacqueline Perrigoue, Ph.D	Merck Research Laboratories			56,000		56,000
David Plachetzki, Ph.D	Howard Hughes Medical Institute			56,000		56,000
George Poulgiannis, Ph.D	Pfizer			56,000		56,000
Selena Sagan, Ph.D	Amgen			56,000		56,000
Zhe Sha, Ph.D	Novartis			70,000		70,000
Maija Slaidina, Ph.D	Howard Hughes Medical Institute			56,000		56,000
Aaron Stephan, Ph.D	Department of Energy			56,000		56,000
Esteban Toro, Ph.D	Howard Hughes Medical Institute			56,866		56,866
Feng Wang, Ph.D	Howard Hughes Medical Institute			56,000		56,000
Xin Wang, Ph.D	Pfizer			84,000		84,000
J. Bradley Zuchero, Ph.D	Howard Hughes Medical Institute			56,000		56,000
Hun-Way Hwang, Ph.D	Howard Hughes Medical Institute				\$ 28,000	28,000
Kimberly Tu, Ph.D.	The Ellison Medical Foundation/AFAR				3,757	3,757
		\$ 5,580,000	\$ 2,688,715	\$ 1,204,866	\$ 31,757	\$ 9,505,338

LIFE SCIENCES RESEARCH FOUNDATION
Notes To Financial Statements
May 31, 2013 and 2012

(See Independent Accountant's Review Report)

Note 4: Escrow Payable

Unexpended funds of a research grant may be held in escrow, if the recipient so elects, until the end of the three-year fellowship. (This option is not available to recipients sponsored by the Department of Energy.) Otherwise, all unexpended funds must be returned to the sponsor. The maximum amount which can be set aside in escrow in any year is \$5,000. In order to receive the balance in the escrow fund at the end of the three-year fellowship, the recipient cannot seek employment with a for-profit organization. All forfeited escrow balances are deemed to be gifts to the Foundation. The escrow balances do not earn interest.

As of May 31, 2013 and 2012, the escrow payable balance was \$84,365 and \$84,185, respectively. For the years ended May 31, 2013 and 2012, there were escrow forfeitures of \$11,026 and \$0, respectively.

Note 5: Grant Forfeitures

At the discretion of the donors, any remaining restricted grant advances that are either held for recipients who terminated their research grants or remain unexpended at the end of the grant period may either be:

- a. Returned to the sponsor.
- b. Applied to another research grant recipient.
- c. Reclassified as a gift to the Foundation.

For the years ended May 31, 2013 and 2012, there were grant forfeitures of \$79,333 and \$28,000, respectively

Note 6: Minimum Investment Return and Distribution Requirement

Even though the Foundation has elected to be treated as a publicly-supported organization, it is required to continue to file its annual exempt organization federal return as a private foundation for the next 5 years. A private foundation must currently distribute its minimum investment return in order to avoid the excise tax for failure to distribute income. The minimum investment return is an income equivalent which is essentially determined by multiplying the aggregate fair market value of the Foundation's assets by 5%. For the years ended May 31, 2013 and 2012, the minimum amounted to \$127,133 and \$93,711, respectively.

The Foundation met these distribution requirements by making qualifying distributions in the years ended May 31, 2013 and 2012, of \$3,332,870 and \$2,685,280, respectively. The excesses generated can be applied to offset future distribution requirements.

LIFE SCIENCES RESEARCH FOUNDATION
Notes To Financial Statements
May 31, 2013 and 2012

(See Independent Accountant's Review Report)

Note 6: Minimum Investment Return and Distribution Requirement (Continued)

A summary of the excess distribution carryovers to future years is as follows:

Year Incurred	Amount	Expiration Date
May 31, 2009	\$ 1,188,773	May 31, 2014
May 31, 2010	1,542,910	May 31, 2015
May 31, 2011	2,210,022	May 31, 2016
May 31, 2012	2,591,509	May 31, 2017
May 31, 2013	<u>3,205,737</u>	May 31, 2018
	<u>\$ 10,738,951</u>	

Note 7: Unrestricted Grants

The Foundation receives unrestricted grants from sponsors for administrative fees, which are assessed annually and are collected along with the sponsors' grant payments for fellowship awards. The total administrative fees collected for the years ended May 31, 2013 and 2012, were \$61,360 and \$61,120, respectively.

Note 8: Temporarily Restricted Net Assets

The Foundation has several temporarily restricted funds, which may be expended but only for the purpose and subject to restrictions established by the respective donors. Temporarily restricted net assets were available for the following purposes as of May 31, 2013 and 2012:

	2012		Current Year Activity		2013	
	Contributions	Released From Restrictions	Contributions	Released From Restrictions	Contributions	Released From Restrictions
Website	\$ 53,000	\$ -0-	\$ (25,000)	\$ 28,000		
Research grants	16,995	45,915	(5,000)	57,910		
	<u>\$ 69,995</u>	<u>\$ 45,915</u>	<u>\$ (30,000)</u>	<u>\$ 85,910</u>		
	2011		Prior Year Activity		2012	
	Contributions	Released From Restrictions	Contributions	Released From Restrictions	Contributions	Released From Restrictions
Website	\$ -0-	\$ 53,000	\$ -0-	\$ 53,000		
Research grants	-0-	16,995	-0-	16,995		
	<u>\$ -0-</u>	<u>\$ 69,995</u>	<u>\$ -0-</u>	<u>\$ 69,995</u>		

LIFE SCIENCES RESEARCH FOUNDATION

SUPPLEMENTARY INFORMATION

MAY 31, 2013 AND 2012

LIFE SCIENCES RESEARCH FOUNDATION
Schedules of Research Grants Paid
Years Ended May 31, 2013 and 2012

(See Independent Accountant's Review Report)

		2013	2012
	<u>2008 Program</u>		
Michael Cohen, Ph.D.	Amgen	\$ -0-	\$ 14,000
Yoav Shaul, Ph.D.	Scherring-Plough Corporation	-0-	14,000
		<u>-0-</u>	<u>28,000</u>
	<u>2009 Program</u>		
Sviatoslav Bagriantsev, Ph.D.	Genentech Foundation	-0-	56,000
Hung-Chun Chang, Ph.D.	The Ellison Medical Foundation	-0-	56,000
Ilana Chefetz-Menaker, Ph.D.	Roche	-0-	56,000
Salvatore Chiantia, Ph.D.	Howard Hughes Medical Institute	-0-	56,000
Guo N. Huang, Ph.D.	O'Donnell Foundation	-0-	56,000
Christian Kastrup, Ph.D.	Johnson & Johnson	-0-	14,000
Enrico Magnani, Ph.D.	Howard Hughes Medical Institute	-0-	56,000
Lauren Mashburn-Warren, Ph.D.	Howard Hughes Medical Institute	-0-	56,000
Nitin Phadnis, Ph.D.	Howard Hughes Medical Institute	-0-	56,000
Xianfeng Xu, Ph.D.	Life Sciences Research Foundation	-0-	14,112
Keren Ziv, Ph.D.	Pfizer	-0-	42,000
		<u>-0-</u>	<u>518,112</u>
	<u>2010 Program</u>		
Evren Azeloglu, Ph.D	Howard Hughes Medical Institute	42,000	56,000
Chase Beisel, Ph.D	The Gordon and Betty Moore Foundation	-0-	1,201
Arpita Bose, Ph.D	Howard Hughes Medical Institute	56,000	56,000
Daniel Chitwood, Ph.D	The Gordon and Betty Moore Foundation	56,000	56,000
Fernando Cruz-Guilloty, Ph.D	Howard Hughes Medical Institute	56,000	56,000
Xin Duan, Ph.D	Howard Hughes Medical Institute	42,000	56,000
Justin Gerke, Ph.D	Merck Research Laboratories	-0-	14,000
Hun-Way Hwang, Ph.D	Howard Hughes Medical Institute	46,667	56,000
Carla Klattenhoff, Ph.D	Novartis	46,667 (2)	56,000
Daryl Klein, Ph.D	Howard Hughes Medical Institute	56,000	56,000
Katherine Ralston, Ph.D	Howard Hughes Medical Institute	18,666 (2)	56,000
Thomas Ream, Ph.D	The Gordon and Betty Moore Foundation	56,000	56,000
Ashley Shade, Ph.D	The Gordon and Betty Moore Foundation	56,000 (1)	56,000
Kimberly Tu, Ph.D	The Ellison Medical Foundation/AFAR	56,000	52,243
Julian Wong, Ph.D	Pfizer	56,000	56,000
David Zhang, Ph.D	Howard Hughes Medical Institute	-0- (2)	42,000
		<u>644,000</u>	<u>781,444</u>

LIFE SCIENCES RESEARCH FOUNDATION
Schedules of Research Grants Paid (Continued)
Years Ended May 31, 2013 and 2012

(See Independent Accountant's Review Report)

		2013	2012
<u>2011 Program</u>			
Justin Ashworth, Ph.D	The Gordon and Betty Moore Foundation	56,000	56,000
Hoo Sun Chung, Ph.D	The Gordon and Betty Moore Foundation	56,000	56,000
Julio Cordero, Ph.D	Lilly Research Laboratories	56,000 (1)	56,000
Magdia De Jesus, Ph.D	Howard Hughes Medical Institute	56,000	56,000
Ylli Dokساني, Ph.D	The Ellison Medical Foundation/AFAR	70,000 (1)	56,000
Cara Haney, Ph.D	The Gordon and Betty Moore Foundation	56,000	56,000
Wenqian Hu, Ph.D	Merck Research Laboratories	56,000 (2)	56,000
Karen Litwa, Ph.D	Howard Hughes Medical Institute	56,000	56,000
Cora MacAlister, Ph.D	The Gordon and Betty Moore Foundation	56,000	56,000
Babak Momeni, Ph.D	The Gordon and Betty Moore Foundation	56,000	56,000
Gautham Nair, Ph.D	Howard Hughes Medical Institute	56,000	56,000
Jacqueline Perrigone, Ph.D	Merck Research Laboratories	56,000	56,000
David Plachetzki, Ph.D	Howard Hughes Medical Institute	56,000	56,000
George Pouligiannis, Ph.D	Pfizer	56,000	56,000
Yan Qi , Ph.D	The Ellison Medical Foundation/AFAR	-0- (2)	56,000
Selena Sagan, Ph.D	Amgen	56,000	56,000
Zhe Sha, Ph.D	Novartis	56,000	42,000
Maija Slaidina, Ph.D	Howard Hughes Medical Institute	56,000	56,000
Aaron Stephan, Ph.D	Department of Energy	56,000	56,000
Esteban Toro, Ph.D	Howard Hughes Medical Institute	55,134	56,000
Feng Wang, Ph.D	Howard Hughes Medical Institute	56,000	56,000
Xin Wang, Ph.D	Pfizer	28,000 (2)	56,000
J. Bradley Zuchero, Ph.D	Howard Hughes Medical Institute	56,000	56,000
		<u>1,217,134</u>	<u>1,274,000</u>
<u>2012 Program</u>			
Anand Balasubramani, Ph.D	Howard Hughes Medical Institute	56,000	-0-
Harvey Chin, Ph.D	Merck Research Laboratories	55,285	-0-
Seemay Chou, Ph.D	Howard Hughes Medical Institute	56,000	-0-
David Dodd, Ph.D	ISIS Pharmaceuticals	56,000 (1)	-0-
Jamie Fitzgerlad, Ph.D	The Ellison Medical Foundation/AFAR	56,000	-0-
Gregory Hamilton, Ph.D	Genetech Foundation	56,000	-0-
Euiseok Kim, Ph.D	Biogen IDEC	56,000	-0-
Tung Le, Ph.D	The Gordon and Betty Moore Foundation	56,000	-0-
Amy Ma, Ph.D	Howard Hughes Medical Institute	56,000	-0-
Daniel Mandell, Ph.D	Howard Hughes Medical Institute	56,000	-0-
Mathieu Mateo, Ph.D	Merck Research Laboratories	56,000	-0-
Alison Narayan, Ph.D	Life Science Research Foundation	56,000	-0-
Ting Pang, Ph.D	Howard Hughes Medical Institute	56,000	-0-
Alexandre Persat, Ph.D	The Gordon and Betty Moore Foundation	56,000	-0-
Monica Rodrigo - Brenni, Ph.D	The Ellison Medical Foundation/AFAR	56,000	-0-
Hannah Seidel, Ph.D	The Ellison Medical Foundation/AFAR	56,000	-0-
Mark Sheffield, Ph.D	The Ellison Medical Foundation/AFAR	56,000	-0-
Anthony Studer, Ph.D	Department of Energy	56,000	-0-
Elizabeth Thatcher, Ph.D	Howard Hughes Medical Institute	56,000	-0-
Yusuf Tufail, Ph.D	Howard Hughes Medical Institute	56,000	-0-
Rachel Vannette, Ph.D	The Gordon and Betty Moore Foundation	56,000	-0-
Michael White, Ph.D	Howard Hughes Medical Institute	56,000	-0-
Joshua Widhalm, Ph.D	The Gordon and Betty Moore Foundation	56,000	-0-
Li Yang, Ph.D	The Gordon and Betty Moore Foundation	56,000	-0-
		<u>1,343,285</u>	<u>-0-</u>
		<u>\$ 3,204,419</u>	<u>\$ 2,601,556</u>

(1) A portion of this research grant was paid out of unrestricted funds. The sponsor's matching grant will be received in the year ending May 31, 2014.

(2) Recipient cancelled the remainder of this research grant during the year ended May 31, 2013.

LIFE SCIENCES RESEARCH FOUNDATION
Schedule of Administrative Expenses
Years Ended May 31, 2013 and 2012

(See Independent Accountant's Review Report)

	<u>2013</u>	<u>2012</u>
Annual conference	\$ 82,452	\$ 34,655
Office expenses	32,232	37,011
Legal and accounting	12,075	11,150
Administrative expenses (Princeton University)	<u>1,355</u>	<u>268</u>
	<u>\$ 128,114</u>	<u>\$ 83,084</u>

